Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies

Marta Nerone(Ente Ospedaliero Cantonale), Rossella Graffeo(Ente Ospedaliero Cantonale)

Cancers

June 23, 2023

10.3390/cancers15133305

Cited by 11

Related Papers

High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel

|Annals of Oncology|2001|151

Biological Therapies Beyond PARP-Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations

|Preprints.org|2023|1